Business Wire

NY-FINSBURY-GLOVER-HERNG

7.7.2020 12:02:08 CEST | Business Wire | Press release

Share
Finsbury, The Glover Park Group and Hering Schuppener to Form One Global Firm

Finsbury, The Glover Park Group (GPG) and Hering Schuppener are joining together to create the preeminent global strategic communications and public affairs consultancy. The new firm, Finsbury Glover Hering, will combine the complementary strengths of three of the world’s most respected advisory firms to counsel chief executives, boards and leaders at public and private companies, leading institutions and nonprofit organizations. The combination formalizes the strategic partnership between the three WPP companies, which was formed by Finsbury and Hering Schuppener in 2016 and which GPG joined in 2017.

At a time when companies and institutions face heightened expectations of purpose and transparency, as well as increased public and stakeholder scrutiny, Finsbury Glover Hering is uniquely equipped to provide integrated, tailored solutions to help organizations navigate the financial, legal, regulatory, societal and stakeholder complexities they must consider in shaping their communications. Clients will benefit from Finsbury Glover Hering’s global network of nearly 700 experts in 18 offices in the world’s major financial, government, business and cultural centers, where the firm builds on strong local foundations forged through decades of experience.

The new firm will lead the industry in:

  • Public affairs and issues management, with deep policy expertise, a reputation for results and unmatched networks in the world’s capitals;
  • Capital markets communications, having advised on more than 1,500 transactions with a total value of more than $2 trillion over the past decade alone; and
  • Corporate, crisis and transformation communications, successfully positioning CEOs and other leaders, steering major public and private companies through high-stakes moments of change and helping launch or re-launch organizations to industry leader status.

Finsbury Glover Hering will launch in early 2021. Finsbury founder Roland Rudd and GPG founder Carter Eskew will co-chair the new firm. Alexander Geiser, Managing Partner at Hering Schuppener, will serve as Chief Executive Officer with the support of seasoned global and regional management teams.

Finsbury Glover Hering will be driven by the highly entrepreneurial spirit that inspired its founder firms and intends to offer equity to recruit, retain and incentivize the best established and emerging talent in communications and public affairs. The management team will be investing in the new firm and will own 49.99% of the company alongside WPP, which will retain a majority interest. Mark Read, the CEO of WPP, will also join the Board of Directors of the newly integrated company.

Mark Read said: “We see in Finsbury Glover Hering a tremendous opportunity to establish a new global powerhouse in the strategic communications industry alongside a very talented and highly respected group of leaders. It also aligns with WPP’s strategy of creating simpler, stronger and more integrated client offers.”

Roland Rudd, co-Chairman and founder of Finsbury, commented: “Each of our firms is best in class and together create a new global standard for strategic advice and communications - we’d like to thank our clients for the trust they have placed in us as individual firms over the last decades.”

“We founded GPG with a highly entrepreneurial spirit, and we’re thrilled that we can now also offer a more sustainable value proposition to future generations,” said co-Chairman Carter Eskew.

CEO Alexander Geiser said: “With one global brand, balance sheet and governance, we are formally implementing what has long been reality for us. One firm, one team.”

The company will be headquartered in New York City, with operations in Abu Dhabi, Beijing, Berlin, Brussels, Dubai, Dublin, Düsseldorf, Frankfurt, Hong Kong, London, Los Angeles, Moscow, Riyadh, Shanghai, Singapore, Tokyo and Washington, D.C.

About Finsbury Glover Hering

Finsbury Glover Hering is a new preeminent global strategic communications advisory firm, headquartered in New York City, with almost 700 multidisciplinary experts across the world’s major financial, government, business and cultural centers. The company was formed through the merger of the leading strategic communications consultancies Finsbury, The Glover Park Group (GPG) and Hering Schuppener. The firm provides combined support in Government Relations & Policy and Advocacy, Corporate Reputation & Leadership Strategies, Crisis & Issues Management, Transaction & Financial Communications as well as Business Transformation, supported by Research and Insights, Digital Strategy, Media Planning and Creative Solutions.

Finsbury Glover Hering serves its global client base from offices in Abu Dhabi, Beijing, Berlin, Brussels, Dubai, Dublin, Düsseldorf, Frankfurt, Hong Kong, London, Los Angeles, Moscow, New York, Riyadh, Shanghai, Singapore, Tokyo and Washington, D.C.

Find more information visit www.fgh.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye